Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/194134
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbelenda Alonso, Gabriela-
dc.contributor.authorRombauts, Alexander-
dc.contributor.authorGudiol González, Carlota-
dc.contributor.authorGarcía-Lerma, Esther-
dc.contributor.authorPallarès, Natàlia-
dc.contributor.authorArdanuy Tisaire, María Carmen-
dc.contributor.authorCalatayud, Laura-
dc.contributor.authorNiubó, Jordi-
dc.contributor.authorTebé, Cristian-
dc.contributor.authorCarratalà, Jordi-
dc.date.accessioned2023-02-24T16:12:24Z-
dc.date.available2023-02-24T16:12:24Z-
dc.date.issued2022-06-21-
dc.identifier.issn1198-743X-
dc.identifier.urihttps://hdl.handle.net/2445/194134-
dc.description.abstractObjectives: The usefulness of routine microbiological testing for rationalising antibiotic use in hospitalised patients with community-acquired pneumonia (CAP) continues to be a subject of debate. We aim to determine the effect of positive microbiological testing on antimicrobial de-escalation and clinical outcomes in CAP. Methods: A retrospective analysis of a prospectively collected cohort of non-immunosuppressed adults hospitalised with CAP was performed. The primary study outcome was antimicrobial de-escalation. Secondary outcomes included 30-day case-fatality rate, adverse events, and CAP recurrence. Adjustment for confounders was performed by inverse probability weighting propensity score, logistic regression, and cause-specific Cox model. Results: Of 3677 patients with CAP, 1924 (52.3%) had any positive microbiological test. Antimicrobial de-escalation was performed in 648/1924 (33.7%) of patients with positive microbiological testing and in 179/1753 (10.2%) of those with non-positive results. When propensity score was entered into the multivariate analysis, positive microbiological testing (adjusted OR (AOR)], 2.59; 1.96-3.41) and clinical stability at day 3 (AOR 1.87; 1.45-2.10) were two of the main factors independently associated with antimicrobial de-escalation. After applying an adjusted cause-specific Cox model, antimicrobial de-escalation was not associated with a higher 30-day case-fatality rate (adjusted hazard ratio (AHR), 0.44 (95% CI, 0.14-1.43)), higher frequency of adverse events (AHR, 0.77 (95% CI, 0.53-1.12)), or CAP recurrence (AHR, 0.65 (95% CI, 0.35-1.14)). Discussion: Antimicrobial de-escalation was more often performed in hospitalised patients with CAP who had positive microbiological tests than in those with non-positive results, and it did not adversely affect relevant clinical outcomes.-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherEuropean Society of Clinical Microbiology and Infectious Diseases-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.cmi.2022.06.021-
dc.relation.ispartofClinical Microbiology and Infection, 2022, vol. 28, num. 12, p. 1602-1608-
dc.relation.urihttps://doi.org/10.1016/j.cmi.2022.06.021-
dc.rightscc by (c) Abelenda Alonso, Gabriela et al., 2022-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationPneumònia-
dc.subject.classificationMedicaments antibacterians-
dc.subject.classificationMicrobiologia-
dc.subject.otherPneumonia-
dc.subject.otherAntibacterial agents-
dc.subject.otherMicrobiology-
dc.titleEffect of positive microbiological testing on antibiotic de-escalation and outcomes in community-acquired pneumonia: a propensity score analysis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec726128-
dc.date.updated2023-02-24T16:12:24Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid35809784-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
726128.pdf253.68 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons